TABLE 2.
Immune response profile in subset of highly protected macaquesa
| Viremia level and macaque no. (group)b | Peak responses prechallenge (IFN-γ secretion [SFC/106 PBMC])
|
Responses at challenge
|
Rectal antibodyc
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (IFN-γ secretion [SFC/106 PBMC])
|
Binding antibody titer
|
CD8AA (% suppression) | Proliferation (SI)
|
|||||||||||||
| Env | Rev | Gag | Nef | Env | Rev | Gag | Nef | α-SIVgp120 | α-peptomer | gp120 | ALD-SIV | p27 | IgG | IgA | ||
| Undetectable viremia | ||||||||||||||||
| 7 (V) | 324 | 174 | 73 | 53 | 10 | 150 | 47 | 0 | 0 | 7 | − | |||||
| 9 (V) | 351 | 374 | 351 | 374 | 100 | 16 | 89 | 0 | 0 | 9 | − | |||||
| 38 (II) | 146 | 36 | 720 | 10 | 14 | 166 | 125,000 | 0 | 24 | 6.2 | ||||||
| 41 (IV) | 712 | 336 | 847 | 60 | 7 | 0 | 34 | 0 | 270,000 | 95 | 0 | 4.7 | 0 | − | 4.4 | |
| Clearance or strong control of viremia | ||||||||||||||||
| 5 (V) | HB | HB | HB | HB | 180 | 1,350 | 22 | 0 | 0 | − | − | |||||
| 15* (IV) | 814 | 87 | HB | 154 | 26 | 6 | HB | 0 | 85,000 | 1 | 3.1 | 4.5 | 2.1 | − | 2 | |
| 28* (II) | 1,198 | 190 | 440 | 70 | 20 | 143 | 82,000 | 0 | 0 | 2.6 | 4.6 | 118 | 17.6 | |||
| 32* (III) | 946 | 967 | 607 | 183 | 83 | 33 | 25,600 | 0 | 0 | 0 | − | − | ||||
| Control at threshold of viremia | ||||||||||||||||
| 4* (III) | 774 | 407 | 170 | 113 | 193 | 170 | 92,000 | 28 | 7.1 | 0 | − | − | ||||
| 29 (III) | 1,800 | 296 | 450 | HB | HB | HB | 145,000 | 92 | 0 | 0 | 25 | − | ||||
| 33* (IV) | 70 | HB | 194 | HB | HB | HB | HB | HB | 25,600 | 19 | 0 | 0 | 2.4 | 7 | − | |
| 40 (III) | 1,054 | 280 | 310 | 632 | 243 | 310 | 63,000 | 68 | 3.3 | 0 | − | 2 | ||||
a
ELISPOT responses with medium backgrounds of >250 SFC are marked “HB” (high background). The resulting mean background levels for data shown are 121 SFC for Env, Rev, and Nef and 138 SFC for Gag.
b
An asterisk denotes MamuA*01. CD8AA, CD8+-T-cell antiviral activity; SI, stimulation index; ALD-SIV, aldrithiol-treated SIV.
c
Rectal anti-SIV gp120 IgG and IgA antibody levels are reported as the fold increase in the OD of vaccinated macaques relative to the controls at week 38 postimmunization. −, an increase of <2 compared to controls.